DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.
Source: onclive.com
Stay updated with breaking news from Data Emerges For. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.